Press releases

Newly approved devices include the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

Study to evaluate clinical outcomes and economic value of the Vercise™ Deep Brain Stimulation (DBS) System.

The first implant of the S-ICD System performed in Hong Kong.

Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...

Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...

MADIT-CRT long-term follow-up results presented at the American College of Cardiology and published in the New England Journal of Medicine.

Includes late breaking clinical trial assessing use of the Boston Scientific CRT-D therapy in patients with mild heart failure

Recognition is for delivering world class results and demonstrating a strong culture of operational excellence at Maple Grove, Minnesota manufacturing facility.

First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes.

Newest bare metal stent technology features advanced architecture and provides physicians with enhanced treatment option for patients

Appointment fills a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from eleven to twelve.

Boston Scientific will participate in the healthcare conference on March 11 in Miami Beach. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on March 4 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in both healthcare conferences on February 26 in New York City. Learn how to watch the webcast or replay.

Fully covered metal stent provides new treatment option for patients with refractory benign esophageal strictures

System provides physicians new option for treating complete blockages in the major arteries of the leg

Fourth quarter marks third consecutive quarter of improved performance.

Boston Scientific will participate in the healthcare conference on February 12 in New York. Learn how to watch the webcast or replay.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and full year ended December 31, 2013. Learn how to tune in.

Global leader in complex cardiac interventions to play key role in driving innovative medical solutions.

Boston Scientific will participate in the healthcare conference on January 14 in San Francisco. Learn how to watch the webcast or replay.

Latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient care.

Appointment will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from ten to eleven.

Represents important milestone toward making WATCHMAN device available to patients with atrial fibrillation.

Data presented at NANS 2013 show highly significant reduction in pain and high trial therapy success rate in the treatment of chronic pain.

Companies will collaborate to provide promotional support for stent system in U.S. hospitals

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...

Boston Scientific will participate in the healthcare conference on December 3 in New York. Learn how to watch the webcast or replay.

Brings more than 20 years of financial and healthcare industry experience, including extensive knowledge of the medtech industry.

Proprietary shaft design enables better control in hard-to-navigate vessels

First system to selectively stimulate targeted areas of the brain to manage symptoms of debilitating disease

Patients In Germany receive new transcatheter aortic valve implantation devices specially designed for total control and accurate deployment.

Boston Scientific will participate in the healthcare conference on November 12 in Scottsdale, AZ. Learn how to watch the webcast or replay.

Advances Boston Scientific's ability to more comprehensively serve the rapidly expanding global EP market.

New data demonstrate successful deployment in all 120 patients with no severe paravalvular regurgitation at 30 days

Boston Scientific will participate in the healthcare conference on November 12. Learn how to watch the webcast or replay.

REDUCE-HTN data presented today at TCT demonstrate excellent safety profile.

Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...

Transcatheter Aortic Valve Replacement (TAVR) device offers precise positioning and placement, offering physicians unprecedented control.

Jeffrey Capello to transition out of CFO role at year-end

"We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation,” said CEO Mike Mahoney.

Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbations

Award recognizes innovative S-ICD® System, the world's first and only subcutaneous implantable defibrillator.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ending September 30, 2013. Learn how to tune in.

MAJESTIC trial to study self-expanding DES System designed to treat superficial femoral artery (SFA) lesions.

University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity.

Re-ROUTE trial data presented at VIVA 2013 late-breaking session

Agreement settles all stent-related disputes between the companies.